<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442780</url>
  </required_header>
  <id_info>
    <org_study_id>204PD203</org_study_id>
    <secondary_id>EUDRA CT NO: 2007-000398-47</secondary_id>
    <nct_id>NCT00442780</nct_id>
  </id_info>
  <brief_title>Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease</brief_title>
  <acronym>MOBILE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is
      tolerated when given at different doses to patients with early-stage Parkinson's Disease.

      This study will also explore:

        -  How BIIB014 is affected when given to patients with early-stage Parkinson's Disease
           (this will be done by measuring the levels of BIIB014 in the blood at several different
           times during the study), and

        -  The activity of BIIB014 when given to early Parkinson's patients (this will be done by
           performing different Parkinson's Disease assessments and other tests during the study).

      Patients who enter this study will be randomly assigned to receive either BIIB014 or a
      placebo but because the study is blinded, neither they nor their study doctor will know which
      study treatment they are taking.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and proportion of subjects with adverse events</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of clinical laboratory parameters.</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of vital signs.</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of ECG parameters.</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess PK by measuring concentrations of BIIB014 and its N-acetyl metabolite in blood plasma.</measure>
    <time_frame>up to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore BIIB014 activity by evaluating standard Parkinson's disease assessments.</measure>
    <time_frame>up to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the PK/pharmacodynamic relationships for BIIB014.</measure>
    <time_frame>up to end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level A of BIIB014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level B of BIIB014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level C of BIIB014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level D of BIIB014</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB014</intervention_name>
    <description>oral administration of BIIB014 per dose, schedule,and duration specified in protocol</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent and any authorizations required by local law.

          -  Must carry a diagnosis of idiopathic Parkinson's Disease(PD), without any other known
             or suspected cause of parkinsonism, according to the UK Parkinson's Disease Society
             Brain Bank Clinical Diagnostic Criteria. Initial diagnosis of PD must have been made
             within the 5 years prior to Screening with at least two or more of the following
             cardinal signs being present: bradykinesia, resting tremor, rigidity, and postural
             instability.

          -  Must be modified Hoehn &amp; Yahr Stage 1 to 2.5 (inclusive).

          -  Must have a baseline UPDRS (Part III) motor score of at least 10.

          -  Subjects may be receiving an anticholinergic agent and/or MAO-B inhibitor (if they
             have been on a stable dose of that medication for at least 4 weeks prior to study
             entry) but must not be receiving any other PD medication.

        Exclusion Criteria:

          -  A Mini Mental State Examination (MMSE) score &lt;26.

          -  History or clinical features consistent with an atypical parkinsonian syndrome.

          -  Any significant non-PD central nervous system disorder.

          -  Any significant AXIS I psychiatric disease as defined by the Diagnostic and
             Statistical Manual of Mental Disorders.

          -  History of cognitive or neuropsychiatric conditions.

          -  History of surgical intervention for PD.

          -  History of L-DOPA-induced motor or non-motor complication.

          -  History of malignancy.

          -  History of severe allergic or anaphylactic reactions to any drug.

          -  Clinically significant renal dysfunction.

          -  HbA1c &gt;7.0%.

          -  Clinically significant baseline ECG.

          -  Orthostatic hypotension.

          -  Treatment with L-DOPA/carbidopa or L-DOPA/benserazide for more than 6 cumulative
             months at anytime since subject's initial PD diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen Idec, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cambridge, MA USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Sites</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>early Parkinson's Disease</keyword>
  <keyword>MOBILE</keyword>
  <keyword>BIIB014</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

